Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer

References

• Berry PA, Maitland NJ, Collins AT. Androgen receptor signalling in prostate. Effects of factors on normal and cancer stem cells. Mol Cell Endocrinol 2008;288:30–7.
   PubMed Web of Science ®Google Scholar
• Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276–308.
   PubMed Web of Science ®Google Scholar
• Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 2003;36:462–9.
   PubMed Web of Science ®Google Scholar
• Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499–512.
   PubMed Web of Science ®Google Scholar
• Cohen P. The role of protein phosphorylation in human health and disease. Eur J Biochem 2001;268:5001–10.
   PubMedGoogle Scholar
• Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase as targets for anticancer drugs. Trends Mol Med 2002;8:17–22.
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) in signalling in cancer. Gene 2006;366:2–16.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1–11.
   PubMed Web of Science ®Google Scholar
• Ratan HL, Gescher A, Steward WP, Mellon JK. ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int 2003;92:890–5.
   PubMed Web of Science ®Google Scholar
• Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res 2006;83:1005–16.
   PubMed Web of Science ®Google Scholar
• Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007;19:2003–12.
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242–8.
   PubMed Web of Science ®Google Scholar
• Pandaya NM, Dhalla NS, Santani DD. Angiogenesis – a new target for future therapy. Vasc Pharmacol 2006;44:265–74.
   PubMed Web of Science ®Google Scholar
• Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 2008;76:15–22.
   PubMed Web of Science ®Google Scholar
• Semino CE, Kamm RD, Lauffenburger DA. Autocrine EGF receptor activation mediates endothelial cell migration and vascular morphogenesis induced by VEGF under interstitial flow. Exp Cell Res 2006;312:289–98.
   PubMed Web of Science ®Google Scholar
• Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584–9.
   PubMed Web of Science ®Google Scholar
• Barton J, Blackledge G, Wakeling A. Growth factor and their receptors: new targets for prostate cancer therapy. Urology 2001;58:114–22.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 2008;34:37–48.
   PubMed Web of Science ®Google Scholar
• Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetenz J, et al. Protein kinases as targets for anticancer agents: from inhibitor to useful drugs. Pharmacol Ther 2002;93:79–98.
   PubMed Web of Science ®Google Scholar
• Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, et al. Design and structure–activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 1999;42:5369–89.
   PubMed Web of Science ®Google Scholar
• Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinase as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999;82:207–18.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10:784–93.
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Boffey R, et al. ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis and tumor growth following oral administration. Cancer Res 2002;62; 4645–55.
   PubMed Web of Science ®Google Scholar
• Kubo K, Shimizu T, Ohyama S, Murooka H, Iwai A, Nakamura K, et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure–activity relationships and antitumor activities of N-phenyl–N’{4-(4-quinolyloxy)phenyl}ureas. J Med Chem 2005;48:1359–66.
   PubMed Web of Science ®Google Scholar
• Dai Y, Hartandi K, Soni NB, Pease LJ, Reuter DR, Olson AM, et al. Identification of aminopyrazolopyridine ureas as potent VEGFR/ PDGFR multitargeted kinase inhibitors. Bioorg Med Chem Lett 2008;18:386–90.
   PubMed Web of Science ®Google Scholar
• Frey RR, Curtin ML, Albert DH, Glaser KB, Pease LJ, Soni NB, et al. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem 2008;51:3777–87.
   PubMed Web of Science ®Google Scholar
• Bouey-Bencteux E, Loison C, Pommery N, Houssin R, Hénichart JP. Synthesis and antiproliferative properties of 4-aminoquinazoline derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity. Anticancer Drug Des 1998;13:893–922.
   PubMedGoogle Scholar
• Desroses M, Laconde G, Telliez A, Piron MC, Pommery N, Depreux P, et al. Development of new anilinoquinazolines, potentially inhibitor of the tyrosine kinase activity of the EGF receptor. Fund Clin Pharmacol 2004;18:593–9.
   Google Scholar
• Telliez A, Desroses M, Pommery N, Briand O, Farce A, Laconde G, et al. Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells. ChemMedChem 2007;2:318–32.
   PubMed Web of Science ®Google Scholar
• Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262–7.
   PubMed Web of Science ®Google Scholar
• Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, et al. Studies leading to the identification of ZD1839 (Iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem 2001;11:1911–14.
   Web of Science ®Google Scholar
• Barber HJ, Washboum K, Wragg R, Lunt E. A new cinnoline synthesis. Cyclisation of mesoxalyl chloride phenylhydrazones to give substituted 4-hydroxycinnoline-3-carboxylic acids. J Chem Soc 1961;28:28–43.
   Google Scholar
• SYBYL 6.9.1. St. Louis, MO: Tripos Inc.
   Google Scholar
• Clark M, Crammer RD III, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J Comput Chem 1989;10:982–1012.
   Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gary G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42.
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265–72.
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Matsunaga S, Tang J, Maeda Y, Nakano M, Philippe RJ, et al. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg Med Chem Lett 2005;15:2203–7.
   PubMed Web of Science ®Google Scholar
• Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727–48.
   PubMed Web of Science ®Google Scholar
• Wang R, Lai L, Wang S. Further development and validation empirical scoring functions for structure–based binding affinity prediction. J Comput Aided Mol Des 2002;16:11–26.
   PubMed Web of Science ®Google Scholar
• Desroses M, Laconde G, Depreux P, Hénichart JP. Synthesis of unsymmetrical dialkoxy quinazolines. Org Prep Proc Int 2004;36:445–52.
   Web of Science ®Google Scholar
• Furuta T, Sakai T, Senga T, Osawa T, Kubo K, Shimizu T, et al. Identification of potent and selective inhibitors of PDGF receptor autophosphorylation. J Med Chem 2006;49:2186–92.
   PubMed Web of Science ®Google Scholar
• Elliott RD, Thomas HJ, Shaddix SC, Adamson DJ, Brockman RW, Riordan JM, et al. Nitrosoureido nucleosides as potential inhibitors of nucleotide biosynthesis. J Med Chem 1988;31:250–4.
   PubMed Web of Science ®Google Scholar